MedTrace Logo

Safety And Efficacy Study Of Orally Administered Epeleuton In Patients With NAFLD

NCT02941549 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2022-10-12

Study results available
· View outcomes & findings →

Summary

The purpose of this randomised, double-blind, placebo-controlled, parallel group study is to assess the safety and efficacy of orally administered Epeleuton capsules versus placebo in the treatment of adult patients with Non Alcoholic Fatty Liver Disease (NAFLD)

Conditions

  • Non Alcoholic Fatty Liver Disease

Interventions

OTHER

Placebo capsules

DRUG

Epeleuton

Sponsors & Collaborators

  • Afimmune

    lead INDUSTRY

Principal Investigators

  • Philip Newsome, MBChB, FRCPE, Ph.D · University of Birmingham

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-20
Primary Completion
2019-01-02
Completion
2019-03-04

Countries

  • Georgia
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02941549 on ClinicalTrials.gov